Komori
Solasia Pharma K.K. (4597) · PolicyRestated

Executive Bonuses Linked to Development Progress and Licensing Activities

First written in FY2021. 2 of 3 entries say "Restated". Latest entry: FY2025.

3entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021 – FY20252022: 120222023: 120232024: 020242025: 020252026: 12026
Same theme, other companies
Performance-based executive and employee compensation schemeA theme 403 companies write about · 0 as a headwind · 395 as a tailwind

The whole theme swung hardest in 2024: 13 of 118 companies on the "Worse" side.

33 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 191 companies compared. The sentences above are computed from all 191.Comparing 200 of the theme's 416 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「目標達成度は、製品開発品の進捗状況、開発品権利導入・導出の実現状況、予算統制含む経営安定性状況等により算定されます。」

    役員賞与の目標達成度を、製品開発、権利導入・導出及び経営安定性に連動させる方針を継続している。
  2. FY2022RestatedAnnual report

    「目標達成度は、製品開発品の進捗状況、開発品権利導入・導出の実現状況、予算統制含む経営安定性状況等により算定されます。」

    役員賞与の目標達成度を製品開発、権利導入・導出及び経営安定性に連動させる方針を継続している。
  3. FY2021First statedAnnual report

    「Bonuses are paid based on an amount calculated by applying a fixed percentage determined according to position, responsibilities and years in office to base compensation, multiplied by the degree to which targets for the relevant fiscal year have been achieved. The representative director and president calculates the amount, and the board of directors makes the final decision. The degree of target achievement is calculated based on factors including the progress of product development, the completion of licensing in or out of development-product rights, and management stability, including budgetary control.」

    For executive directors responsible for business execution, the Company identifies product-development progress, licensing in and out, and management stability including budgetary control as factors in determining target achievement for bonuses.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Solasia Pharma K.K. yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Executive Bonuses Linked to Development Progress and Licensing Activities | Solasia Pharma K.K. (4597) | Komori